Literature DB >> 27665848

Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells.

Ji Zhang1,2,3, Yi-Rong Ding1, Rui Wang1.   

Abstract

AIM: Tissue transglutaminase (tTG) catalyzes proteins, including β-amyloid (Aβ), to cross-link as a γ-glutamyl-ε-lysine structure isopeptide, which is highly resistant to proteolysis. Thus, tTG plays an important role in protein accumulation in Alzheimer's disease (AD). In the present study, we examined the effect of an irreversible tTG inhibitor, NTU283, on Aβ mimic-induced AD pathogenesis in SH-SY5Y cells.
METHODS: Western blot and in-cell Western analyses were used to detect tTG and isopeptide (representing the enzyme activity of tTG) protein levels. Moreover, Hoechst and PI co-staining was performed, and caspase-3 and caspase-7 activities and the Bax/Bcl-2 ratio were determined to evaluate the effects of NTU283 on apoptosis.
RESULTS: The results confirmed that tTG activity was inhibited by NTU283 20-500 μmol/L in a concentration-dependent manner in SH-SY5Y cells. Contrary to our expectations, however, the isopeptide bonds were increased when cells were co-treated with Aβ and NTU283. In addition, NTU283 alone did not induce apoptosis in SH-SY5Y cells. However, when co-applied with Aβ, NTU283 promoted rather than inhibited Aβ-induced apoptosis. Consistent with the apoptotic rate, pretreating cells with different concentrations of NTU283 and Aβ significantly increased the activities of caspase-3 and caspase-7 as well as the ratio of Bax/Bcl-2.
CONCLUSION: Irreversible inhibition of tTG activity did not block but rather promoted Aβ-induced apoptosis, which indicated that tTG has complex functions in AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27665848      PMCID: PMC5260835          DOI: 10.1038/aps.2016.95

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  54 in total

1.  Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.

Authors:  Steven M Singer; Gina M Zainelli; Maryam A Norlund; John M Lee; Nancy A Muma
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

2.  Unexpected role of surface transglutaminase type II in celiac disease.

Authors:  Luigi Maiuri; Carolina Ciacci; Ida Ricciardelli; Loredana Vacca; Valeria Raia; Antonio Rispo; Martin Griffin; Thomas Issekutz; Sonia Quaratino; Marco Londei
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

3.  Magnetic Fe₃ O ₄ nanoparticles grafted with single-chain antibody (scFv) and docetaxel loaded β-cyclodextrin potential for ovarian cancer dual-targeting therapy.

Authors:  Xiao Huang; Caixia Yi; Yijuan Fan; Yinxing Zhang; Limei Zhao; Zhiqing Liang; Jun Pan
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2014-05-24       Impact factor: 7.328

4.  Transglutaminase 2 inhibits apoptosis induced by calcium- overload through down-regulation of Bax.

Authors:  Sung-Yup Cho; Jin-Haeng Lee; Han-Dong Bae; Eui Man Jeong; Gi-Yong Jang; Chai-Wan Kim; Dong-Myung Shin; Ju-Hong Jeon; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-09-30       Impact factor: 8.718

Review 5.  Tissue transglutaminase (TG2)--a wound response enzyme.

Authors:  Dilek Telci; Martin Griffin
Journal:  Front Biosci       Date:  2006-01-01

Review 6.  Tissue transglutaminase and factor XIII in cartilage and bone remodeling.

Authors:  D Aeschlimann; D Mosher; M Paulsson
Journal:  Semin Thromb Hemost       Date:  1996       Impact factor: 4.180

Review 7.  Tissue transglutaminase in normal and abnormal wound healing: review article.

Authors:  E A M Verderio; T Johnson; M Griffin
Journal:  Amino Acids       Date:  2004-06-21       Impact factor: 3.520

8.  Apoptosis modulatory activities of transiently expressed Bcl-2: roles in cytochrome C release and Bax regulation.

Authors:  Q Hou; E Cymbalyuk; S-C Hsu; M Xu; Y-T Hsu
Journal:  Apoptosis       Date:  2003-12       Impact factor: 4.677

9.  N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cells.

Authors:  Rui Wang; James S Malter; Deng-Shun Wang
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

10.  Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication.

Authors:  S Fleminger; D L Oliver; S Lovestone; S Rabe-Hesketh; A Giora
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

View more
  1 in total

1.  Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease.

Authors:  Cheng-Jie Liang; Jia-Huang Li; Zhen Zhang; Ju-Yan Zhang; Shu-Qun Liu; Jie Yang
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.